US EditionPublished • loading... • Updated
Sigyn Therapeutics Outlines Clinical Pathway for CardioDialysis and Corporate Strategy Amid Nasdaq Rule Changes
Summary by citybuzz.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Sigyn Therapeutics Outlines Clinical Pathway for CardioDialysis and Corporate Strategy Amid Nasdaq Rule Changes
Sigyn Therapeutics, Inc., a developer of dialysis-like therapies for cardiovascular disease and cancer, has outlined its clinical and corporate strategy in a shareholder update. The company’s primary focus is CardioDialysis, a medical device designed to treat cardiovascular disease by reducing inflammatory molecules and cholesterol-transporting lipoproteins during dialysis sessions. Cardiovascular disease remains the leading cause of death world…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
